Literature DB >> 25858666

Recent advances on anti-HIV vaginal delivery systems development.

Sophia G Antimisiaris1, Spyridon Mourtas2.   

Abstract

A review of the recent outcomes regarding technologies to prevent vaginal transmission of HIV, mainly by using antiretroviral (ARV) drugs formulated as microbicides. An introduction about the HIV transmission mechanisms by the vaginal route is included, together with the recent challenges faced for development of successful microbicide products. The outcomes of clinical evaluations are mentioned, and the different formulation strategies studied to-date, with the requirements, advantages, disadvantages and limitations of each dosage-form type, are presented. Finally, the recent attempts to apply various types of nanotechnologies in order to develop advanced microbicide-products and overcome existing limitations, are discussed.
Copyright © 2015 Elsevier B.V. All rights reserved.

Keywords:  AIDS; Formulation; HIV; Microbicides; Mucosal; Nanotechnology; Transmission; Vaginal

Mesh:

Substances:

Year:  2015        PMID: 25858666     DOI: 10.1016/j.addr.2015.03.015

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  12 in total

1.  Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration.

Authors:  John W McBride; Nicola Dias; David Cameron; Robin E Offord; Oliver Hartley; Peter Boyd; Vicky L Kett; R Karl Malcolm
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

2.  Human vaginal fluid contains exosomes that have an inhibitory effect on an early step of the HIV-1 life cycle.

Authors:  Johanna A Smith; Rene Daniel
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177

Review 3.  On-demand microbicide products: design matters.

Authors:  Sravan Kumar Patel; Lisa Cencia Rohan
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

4.  Development of NanoART for HIV Treatment: Minding the Cytochrome P450 (CYP) Enzymes.

Authors:  Narasimha M Midde; Santosh Kumar
Journal:  J Pers Nanomed       Date:  2015-09-10

Review 5.  Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.

Authors:  Ignacio Rodríguez-Izquierdo; Daniel Sepúlveda-Crespo; Jose María Lasso; Salvador Resino; Ma Ángeles Muñoz-Fernández
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-01-12

Review 6.  Dendrimers as Pharmaceutical Excipients: Synthesis, Properties, Toxicity and Biomedical Applications.

Authors:  Ana Santos; Francisco Veiga; Ana Figueiras
Journal:  Materials (Basel)       Date:  2019-12-21       Impact factor: 3.623

Review 7.  High Preventive Effect of G2-S16 Anionic Carbosilane Dendrimer against Sexually Transmitted HSV-2 Infection.

Authors:  Ignacio Rodriguez-Izquierdo; Samanta Gasco; Maria Angeles Muñoz-Fernández
Journal:  Molecules       Date:  2020-06-28       Impact factor: 4.411

Review 8.  Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.

Authors:  Antoinette G Nelson; Xiaoping Zhang; Usha Ganapathi; Zoltan Szekely; Charles W Flexner; Andrew Owen; Patrick J Sinko
Journal:  J Control Release       Date:  2015-08-24       Impact factor: 9.776

9.  Mucoadhesive Vaginal Discs based on Cyclodextrin and Surfactants for the Controlled Release of Antiretroviral Drugs to Prevent the Sexual Transmission of HIV.

Authors:  Fernando Notario-Pérez; Araceli Martín-Illana; Raúl Cazorla-Luna; Roberto Ruiz-Caro; Aitana Tamayo; Juan Rubio; María-Dolores Veiga
Journal:  Pharmaceutics       Date:  2020-04-02       Impact factor: 6.321

10.  Ultra-deformable liposomes containing terpenes (terpesomes) loaded fenticonazole nitrate for treatment of vaginal candidiasis: Box-Behnken design optimization, comparative ex vivo and in vivo studies.

Authors:  Rofida Albash; Yasmina Elmahboub; Kholoud Baraka; Menna M Abdellatif; Ahmed Adel Alaa-Eldin
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.